Arrowhead Pharmaceuticals

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on: 
Tuesday, April 16, 2024
University, CFO, LLP, Champaign–Urbana metropolitan area, Certification, Arrowhead Pharmaceuticals, TILS, PwC, Biotechnology Innovation Organization, BIO, Selection, TIL, SVP, Senior, Patient, OncoMed, Therapy, Biotechnology, SAN, Pharmaceutical industry

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points: 
  • SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
  • The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
  • “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
  • “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Retrieved on: 
Monday, April 15, 2024
Doctor of Philosophy, Denosumab, University, Arrowhead Pharmaceuticals, Eli Lilly, Compensated emancipation, Internal medicine, International development, Employment, HGF, Lundbeck Seattle Biopharmaceuticals, Athira Pharma, Therapy, Senior, Hypophosphatemia, Patient, ALS, DSM-IV codes, Ultragenyx, Drug development, Burosumab, Growth, Pharmaceutical industry

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer.

Key Points: 
  • BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer.
  • “We are pleased to welcome Javier to the team and are confident his insights and guidance will be instrumental as we advance the Company’s next phase of growth,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • Before that, Dr. San Martin served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals, where he managed medical, regulatory, and clinical operations.
  • In addition, Athira today announced, as required by The Nasdaq Stock Market Rules, an equity inducement award to Dr. San Martin, the Company’s new Chief Medical Officer.

RegCell Appoints Leading T-Cell Therapy Expert Steven B. Kanner, Ph.D., to Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Cell, Rachel Haurwitz, Drug discovery, Genetics, Inflammation, Patient, Arrowhead Pharmaceuticals, Research, Bristol Myers Squibb, University, Publication, Reindeer, Microbiology, Regulatory T cell, RNA interference, Immune system, Therapy, Bangladesh Technical Education Board, Book, Astex Pharmaceuticals, Vaccine

"We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.

Key Points: 
  • "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
  • "Dr. Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform.
  • Backed by leading institutional and corporate investors hailing from Japan, RegCell emerges as the next-generation global life science enterprise at the forefront of regulatory T-cell therapies.
  • Central to RegCell's innovation is its 'Precision Epigenetic Reprogramming' platform, which entails the epigenetic reprogramming of CD4+ T-cells into regulatory T-cells.

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, PIN, Arrowhead Pharmaceuticals, Webcast

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal first quarter ended December 31, 2023.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

Retrieved on: 
Thursday, December 21, 2023
Health, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Committee, RNA, Liver, RNA interference, System, CFB, Kidney, Kidney disease, Glomerulonephritis, Translational medicine, Arrowhead Pharmaceuticals, Arrowhead, MBA, Clinical trial, Pharmacokinetics, Complement factor B, Ethics committee, Discovery, Safety, Patient, Pharmaceutical industry

Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.

Key Points: 
  • Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.
  • ARO-CFB is designed to reduce hepatic expression of complement factor B (CFB), which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target.
  • James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “IgAN is the most common glomerular disease worldwide, accounting for up to 40% of all cases of glomerulonephritis.
  • Pending clearance, Arrowhead intends to proceed with AROCFB-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-CFB in up to 66 healthy volunteers and patients with complement mediated kidney disease.

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Life expectancy, Safety, Cataract, RNA interference, Exercise, Arrowhead, Clinical trial, DMPK, DM1, Wheelchair, Pharmacokinetics, Muscle weakness, Messenger, Therapy, Ethics committee, MBA, Committee, Wasting, Myotonia, Arrowhead Pharmaceuticals, Patient, Facial muscles, Discovery, Translational medicine, RNA, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.
  • ARO-DM1 is designed to reduce expression of the dystrophia myotonica protein kinase (DMPK) gene.
  • Treatments have focused on symptomatic management, including physical therapy, exercise, ankle-foot orthoses, wheelchairs, and other assistive devices.
  • Pending clearance, Arrowhead intends to proceed with ARODM1-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-DM1 in up to 48 subjects with DM1.

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

Retrieved on: 
Thursday, November 16, 2023
Genetics, Pharmaceutical, Health, Webcast, Arrowhead Pharmaceuticals, PIN

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal year ended September 30, 2023.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MTV: TRL Christmas, Malignancy, Safety, Fasting, Heart, Risk, AHA, Hypertriglyceridemia, TGS, Apolipoprotein B, Serum, Cleveland Clinic, Baylor College of Medicine, APOC3, American Heart Association, Dyslipidemia, MD, Triglyceride, Doctor of Philosophy, ASCVD, Arrowhead Pharmaceuticals, ANGPTL3, Moyamoya disease, Pharmaceutical industry, Shipbuilding, Medical device, Arrowhead, Medicine, Patient

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.
  • Despite potent LDL-C lowering therapies, residual ASCVD risk persists due in part to high levels of atherogenic TRLs.
  • At 24 weeks, plozasiran durably decreased serum APOC3 to -79%, TGs to -74%, and remnant cholesterol to -63%, while increasing HDL-cholesterol to +68%.
  • Serious TEAEs were not related to plozasiran and were resolved without sequelae, except two subjects with malignancies.

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, European Respiratory Society, RAGE, Asthma, International, Serum, Gastric lavage, TSLP, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Lung, ERS, MUC5AC, Arrowhead Pharmaceuticals, Patient, MMP7, BALF, RNA interference, International Congress on Tuberculosis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.
  • Reduction of serum sRAGE was similar in healthy volunteers and in patients with asthma at the 44 mg dose level.
  • Based on interim blinded safety results from the ongoing study, ARO-RAGE has been well-tolerated to date in healthy volunteers and asthma patients.
  • “Today we announced additional data on multiple programs from our emerging pipeline of first-in-class pulmonary targeted RNAi therapeutic candidates at the European Respiratory Society International Congress.